1-(3-溴丙氧基)-4-氟苯 | 1129-78-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-(3-溴丙氧基)-4-氟苯
• 中文别名: 1-(3-溴代丙氧基)-4-氟苯
• 英文名称: 1-(3-bromopropoxy)-4-fluorobenzene
• CAS: 1129-78-8
• 化学式: C₉H₁₀BrFO
• mdl: MFCD00596629
• 分子量: 233.08
• InChiKey: VKNUENLPKPOOPS-UHFFFAOYSA-N

物化性质

• 沸点：
  155 °C (12 mmHg)
• 密度：
  1.422±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  避免与不相容材料接触，与强氧化剂反应。

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn,Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2909309090
• 危险类别：
  IRRITANT
• 安全说明：
  S37/39
• 储存条件：
  密封储存，应存放在阴凉、干燥的库房中。

SDS

Name:	1-(3-Bromopropoxy)-4-fluorobenzene Material Safety Data Sheet
Synonym:
CAS:	1129-78-8

Section 1 - Chemical Product MSDS Name:1-(3-Bromopropoxy)-4-fluorobenzene Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
1129-78-8	1-(3-Bromopropoxy)-4-fluorobenzene	100	unlisted

Hazard Symbols: XN
Risk Phrases: 20/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation and if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. Lachrymator (substance which increases the flow of tears).
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 1129-78-8: Personal Protective Equipment Eyes: Wear chemical splash goggles.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 155 deg C @12mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: >200 deg C
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H10BrFO
Molecular Weight: 233.08

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
No information found.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, carbon dioxide, hydrogen bromide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 1129-78-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(3-Bromopropoxy)-4-fluorobenzene - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing Group: III
IMO
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing Group: III
RID/ADR
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/22 Harmful by inhalation and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 1129-78-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 1129-78-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 1129-78-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(3-溴丙氧基)-4-氟苯 在 lithium aluminium tetrahydride 、 四(三苯基膦)钯 、 1,3-二甲基巴比妥酸 、 20 % Pd(OH)2/C 、 氢气 、 sodium hydride 、 potassium carbonate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 苯甲酸 、 sodium iodide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 114.67h， 生成 cis-1-[3-(4-fluorophenoxy)propyl]-4-amino-3-methoxypiperidine
  参考文献：
  名称：

  简洁，高效且高度选择性的（+）-（3 S，4 R）-西沙必利不对称合成

  摘要：

  胃动能剂（+）-（3 S，4 R）-西沙必利{（+）-（3 S，4 R）-N（1）-[3'-（4''-氟苯氧基）丙基的简明不对称合成已经开发了来自可商购的起始原料的] -3-甲氧基-4-（2″′-甲氧基-4″′-氨基-5″′-氯苯甲酰胺基）哌啶}。该合成的关键步骤是将锂（R）-N-苄基-N-（α-甲基苄基）酰胺非对映选择性共轭加成至叔丁基5- [ N -3'-（4″-氟苯氧基）丙基-N -烯丙基氨基]戊-2-烯酸酯和用（-）-樟脑磺酰基恶唑烷原位烯酸酯氧化以设定（3 S在产物的哌啶环中发现了，4 R）-构型。该合成从市售的1-（4'-氟苯氧基）-3-溴丙烷分9步进行，总产率为19％。

  DOI：

  10.1016/j.tetasy.2011.08.020
• 作为产物：
  描述：

  4-氟苯酚 、 3-氯-1-丙醇 生成 1-(3-溴丙氧基)-4-氟苯
  参考文献：
  名称：

  尖顶 七。氮杂螺啶衍生的神经病学。

  摘要：

  DOI：

  10.1021/jm00325a015

文献信息

• [EN] 3,4-DIHYDROPYRIMIDINE TRPA1 ANTAGONISTS<br/>[FR] ANTAGONISTES DES TRPA1 CONSTITUÉS PAR DES 3,4-DIHYDROPYRIMIDINES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009147079A1

  公开（公告）日：2009-12-10

  The present invention is related to novel 3,4-dihydropyrimidine compounds of formula (I) having TRPA1 receptor antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the modulation of the TRPA1 receptors in animals, in particular humans.

  本发明涉及具有TRPA1受体拮抗性质的新型3,4-二氢嘧啶化合物（I）的药物组合物，包括这些化合物的化学制备过程以及它们在治疗与动物中TRPA1受体调节相关的疾病，特别是人类中的用途。
• Transition metal- and light-free radical borylation of alkyl bromides and iodides using silane
  作者：Beiqi Sun、Sihan Zheng、Fanyang Mo

  DOI：10.1039/d1cc02134f

  日期：——

  for borylation of alkyl bromides and iodides to alkyl boronic esters under transition metal- and light-free conditions. A series of substrates with a wide range of functional groups were effectively transformed into the borylation products in moderate to good yields. Mechanistic studies, including radical clock experiments and DFT calculations, gave detailed insight into the radical borylation process

  我们报告了在无过渡金属和无光条件下将烷基溴和碘化物硼化为烷基硼酸酯的操作简单和中性的条件。一系列具有广泛功能基团的底物以中等到良好的产率有效地转化为硼酸酯化产物。包括自由基时钟实验和DFT计算在内的机理研究，使人们对自由基硼化过程有了更深入的了解。
• Synthesis, labelling and first evaluation of [¹⁸F]R91150 as a serotonin 5-HT_2Areceptor antagonist for PET
  作者：Ute Mühlhausen、Johannes Ermert、Heinz H. Coenen

  DOI：10.1002/jlcr.1565

  日期：2009.1

  1-(3-bromopropoxy)-4-[18F]fluorobenzene within 190 min starting from no-carrier-added [18F]fluoride. The overall radiochemical yield was 3.8±2% and the specific activity was at least 335 GBq/µmol at the end of the synthesis. First ex vivo studies in mice proved the uptake of [18F]R91150 in the brain. Radiometabolite studies revealed no radiometabolites in the brain, whereas in the plasma at least two could be detected

  在焦虑、抑郁和精神分裂症等精神疾病中，5-HT2A 受体起着重要作用。为了在体内研究它们，人们对使用正电子发射断层扫描 (PET) 进行受体结合研究的选择性和高亲和力放射性配体越来越感兴趣。由于可用的放射性配体有缺点，R91150 是 5-HT2A 受体的选择性和高亲和力配体，用氟 18 标记。这是通过 4-[18F] 氟苯酚和 1-(3-溴丙氧基)-4-[18F] 氟苯在 190 分钟内从未添加载体的 [18F] 氟化物开始的六个步骤中完成的。总放射化学产率为 3.8±2%，合成结束时的比活至少为 335 GBq/μmol。首次在小鼠体内进行的研究证明了 [18F]R91150 在大脑中的吸收。放射性代谢物研究显示大脑中没有放射性代谢物，而在血浆中至少可以检测到两种 pi 后 30 分钟。鼓励进一步的临床前研究评估这种新的 5-HT2A 配体作为 PET 放射性示踪剂的潜力。版权所有 ©
• Indoles
  申请人：Eisai Co., Ltd.

  公开号：US20020019531A1

  公开（公告）日：2002-02-14

  A 1,4-substituted cyclic amine derivative represented by the following formula or a pharmacologically acceptable salt thereof: 1 wherein A, B, C, D, T, Y, and Z each represent a methine or a nitrogen linkage; R 1 , R 2 , R 3 , R 4 , and R 5 each represent a substituent; n represents 0 or an integer of 1 to 3; m represents 0 or an integer of 1 to 6; and p represents an integer of 1 to 3. The compounds have serotonin antagonism. They are therefore clinically useful as medicaments, in particular, for treating, ameliorating, and preventing spastic paralysis. They are also useful as central muscle relaxants for ameliorating myotonia.

  一种由以下公式表示的1,4-取代的环胺衍生物或其药理学上可接受的盐： 其中A、B、C、D、T、Y和Z分别表示亚甲基或氮键合物；R1、R2、R3、R4和R5分别表示取代基；n表示0或1至3的整数；m表示0或1至6的整数；p表示1至3的整数。这些化合物具有5-羟色胺拮抗作用。因此，在临床上作为药物特别有用，用于治疗、改善和预防痉挛性瘫痪。它们还可用作中枢肌肉松弛剂，改善肌张力过高。
• Asymmetric syntheses of 3,4-syn- and 3,4-anti-3-substituted-4-aminopiperidin-2-ones: application to the asymmetric synthesis of (+)-(3S,4R)-cisapride
  作者：Stephen G. Davies、Rosemary Huckvale、James A. Lee、Thomas J.A. Lorkin、Paul M. Roberts、James E. Thomson

  DOI：10.1016/j.tet.2011.12.084

  日期：2012.4

  gives the corresponding 3,4-syn-3-hydroxy-4-aminopiperidin-2-ones in >99:1 dr. The utility of this methodology was successfully demonstrated in a concise asymmetric synthesis of the gastroprokinetic agent (+)-(3S,4R)-cisapride (+)-(3S,4R)-N(1)-[3′-(4″-fluorophenoxy)propyl]-3-methoxy-4-(2‴-methoxy-4‴-amino-5‴-chlorobenzamido)piperidine} in nine steps from commercially available starting materials with

  将（R）-N-苄基-N-（α-甲基苄基）酰胺共轭加成到δ-（N-烯丙基氨基）-α，β-不饱和酯中，然后N-去烯丙基化并环化所得的β，δ -二氨基酯，得到相应的4-氨基哌啶-2-酮，为单一非对映异构体（> 99：1 dr）。随后用LiHMDS脱质子化，并将所得的烯醇锂官能化，得到3,4-抗-3-取代-4-氨基哌啶-2-酮的> 99：1 dr。或者，在共轭加成后形成的中间锂（Z）-β-氨基烯醇盐的原位氧化得到α-羟基-β，δ-二氨基酯，经N-去烯丙基化和环化后得到相应的3,4- syn> 99：1博士中的-3-羟基-4-氨基哌啶-2-酮 该方法的效用是成功地证明在gastroprokinetic剂（+）的简明不对称合成- （3-小号，4 - [R）-cisapride （+） - （3小号，4 - [R ）- Ñ（1） - [3-从商业上可得的起始原料，以九步法制备′-（4″-氟苯氧基）丙基]